Teva filed a new drug application to market a generic version of Actonel, the osteoporosis drug in the U.S., asserting that the Procter & Gamble patent wasn’t valid. However, the validity of the patent was upheld in a ruling by the U.S. District Court of Delaware which rejected Teva’s claims and gives Procter & Gamble Co. the exclusive right to market Actonel in the States.
Teva Pharmaceutical Industries Ltd. (TEVA) announced on Friday that it will appeal the decision.
This entry was posted on Sunday, March 2nd, 2008 at 7:15 pm and is filed under Intellectual Property, Israel IP, Israel Related, News, Patents, drugs, pharmaceuticals, pharmaceuticals and Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Dr. Michael Factor is an Israel Patent Attorney and partner of JMB, Factor & Co. Israel's International IP Firm.
Theme Contempt by Vault9.
Blog at WordPress.com.
